BioCentury | May 26, 2020
Product Development

Understanding and weaponizing immune responses to COVID-19

Human B and T cell responses to the novel coronavirus provide natural biomarkers and blueprints for COVID-19 countermeasures. Virtual presentations hosted Thursday by BioCentury and Repertoire Immune Medicines Inc. showcased emerging work on SARS-CoV-2 antigens...
BioCentury | May 26, 2020
Deals

With trio of COVID deals, Merck takes a page from its Ebola strategy

Merck’s strategy to tackle COVID-19 appears to echo an approach that allowed the pharma to rapidly develop a vaccine for Ebola -- but on a much faster timeline. Merck & Co. Inc. (NYSE:MRK) said Tuesday...
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder  ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...
BioCentury | May 15, 2020
Translation in Brief

Passage’s mouse, dog data for Krabbe disease; plus a predictive model of COVID-19 mortality, Sorrento’s COVID-19 antibody candidate and more

Efficacy for Passage’s Krabbe disease gene therapy  Passage Bio Inc. (NASDAQ:PASG) has presented data supporting an IND it plans to submit next half for PBKR03 to treat Krabbe disease. In mouse and dog models of...
BioCentury | May 15, 2020
Product Development

Repurposed autoimmune therapies head for controlled COVID-19 studies in Europe

Abivax and Immunic are launching COVID-19 trials of their autoimmune therapies in France and Germany, respectively, meeting regulators’ demands for large, controlled studies to demonstrate therapeutic efficacy. In the U.S., the patent office is fast-tracking...
BioCentury | May 8, 2020
Targets & Mechanisms

New Gladstone institutes point to emerging concepts in virology, immunology

The research focuses of new centers replacing the Gladstone Institute of Virology and Immunology highlight how the fields have evolved since its founding in 1991. Like their predecessor, the Gladstone Institute of Virology and the...
BioCentury | May 8, 2020
Politics, Policy & Law

Partnership offers hope for COVID drug development

As the world eyes a return to post-COVID crisis “normalcy,” a robust global recovery will depend on effective treatments and ultimately a vaccine. Yes, more than 400 research and clinical programs are already under way,...
BioCentury | May 6, 2020
Product Development

Learning from AIDS: there’s more than one way to tame a virus

The HHS secretary promised a vaccine within two years. Anthony Fauci urged caution, telling reporters “we don’t have any idea how long it’s going to take to develop a vaccine, if indeed we will be...
BioCentury | May 5, 2020
Politics, Policy & Law

Lawmakers vigilant in watching for COVID-19-related price gouging

A letter from a House of Representatives committee expressing concern over a price hike for a drug that could be used in COVID-19 patients underscores Congress’ readiness to call out what it perceives to be...
Items per page:
1 - 10 of 7235